-
COST-EFFECTIVENESS ANALYSIS OF LIPOSOMAL IRINOTECAN IN COMBINATION WITH OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN (NALIRIFOX) FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS IN GREECE
Aug 11, 2026, 17:16 PM -
MORTALITY, DISEASE BURDEN AND HEALTHCARE RESOURCE USE IN PATIENTS WITH TRANSTHYRETIN AMYLOIDOSIS WITH CARDIAC INVOLVEMENT IN SPAIN: RESULTS FROM THE OVERTTURE GLOBAL STUDY
Aug 11, 2026, 17:16 PM -
TREAT NOW, PROVE LATER? EU5 PAYER PERSPECTIVES ON PRE-SYMPTOMATIC GENE THERAPY FOR HUNTINGTON'S DISEASE
Aug 11, 2026, 17:16 PM -
MIND THE GAP: INEQUITIES IN MARKET ACCESS TIMELINES ACROSS EUROPE
Aug 11, 2026, 17:16 PM -
HEALTHCARE RESOURCE UTILIZATION AND OUTCOMES IN PULMONARY ARTERIAL HYPERTENSION: EVIDENCE FROM A TERTIARY CENTER IN ARGENTINA
Aug 11, 2026, 17:16 PM -
SELECTION OF TREATMENT EFFECT MODIFIERS AND PROGNOSTIC FACTORS IN POPULATION-ADJUSTED INDIRECT COMPARISONS: A REVIEW AND IMPLICATIONS FOR DECISION-MAKING IN NICE
Aug 11, 2026, 17:16 PM -
CLINICAL AND ECONOMIC BURDEN OF GENERALIZED MYASTHENIA GRAVIS IN THE BRAZILIAN SUPPLEMENTARY HEALTHCARE SYSTEM: A REAL-WORLD STUDY (2019-2025)
Aug 11, 2026, 17:16 PM -
EVALUATING THE REAL-WORLD IMPACT OF UPDATED COLORECTAL CANCER SCREENING GUIDELINES IN THE UNITED STATES
Aug 11, 2026, 17:16 PM -
USE OF BIOSIMILARS IN FRENCH COMMUNITY PHARMACIES: A NATIONWIDE ANALYSIS USING OPEN-ACCESS MEDICO-ADMINISTRATIVE DATA (2016-2025)
Aug 11, 2026, 17:16 PM -
FROM PREDICTION TO POLICY: HEALTH TECHNOLOGY ASSESSMENT OF CLINICAL PREDICTION MODELS
Aug 11, 2026, 17:16 PM -
HUMANISTIC BURDEN OF NEUROFIBROMATOSIS TYPE 1 ON PATIENTS AND CAREGIVERS: A SYSTEMATIC LITERATURE REVIEW
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS ANALYSES OF ANTIFIBROTICS FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS: A LITERATURE REVIEW
Aug 11, 2026, 17:16 PM -
HEALTH-RELATED QUALITY OF LIFE IN HEART FAILURE IN SAUDI ARABIA: A COMPARATIVE ASSESSMENT USING THE EQ-5D-5L AND EQ-HWB-9
Aug 11, 2026, 17:16 PM -
OFF-THE-SHELF LLM, HUMAN EXPERT, OR PURPOSE-BUILT AGENT? A CONTROLLED VALIDATION HACKATHON BENCHMARKING THREE APPROACHES TO QUALITY CONTROL OF HEALTH ECONOMIC MODELS
Aug 11, 2026, 17:16 PM -
HEALTH ECONOMIC EVALUATION OF BIOLOGIC TREATMENT SEQUENCES FOR PATIENTS WITH MODERATE-TO-SEVERE ACTIVE CROHN'S DISEASE
Aug 11, 2026, 17:16 PM -
EQ-5D-5L-DERIVED UTILITY DRIVERS OF HRQOL IN HAE AND COMPARISON WITH PATIENT REPORTED QUALITATIVE FINDINGS
Aug 11, 2026, 17:16 PM -
CHARACTERIZING PEOPLE WITH UNTREATED MULTIPLE SCLEROSIS IN REAL-WORLD EVIDENCE: INSIGHTS FROM LITERATURE AND THE GERMAN NEUROTRANSDATA REGISTRY (2018-2024)
Aug 11, 2026, 17:16 PM -
EMPIRICAL ECONOMIC EVALUATION AND ENVIRONMENTAL IMPACT ASSESSMENT OF REUSABLE VERSUS SINGLE-USE CATHETERS FOR CLEAN INTERMITTENT CATHETERISATION
Aug 11, 2026, 17:16 PM -
CALCULATING THE REAL-WORLD INCREMENTAL COST-EFFECTIVENESS RATIO FOR DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN THE SECOND-LINE SETTING FOR RELAPSED REFRACTORY MYELOMA IN BRITISH COLUMBIA
Aug 11, 2026, 17:16 PM -
THE EVOLVING ACCESS AND POLICY CONCERNS OF GLOBAL PHARMACEUTICAL MANUFACTURERS: AN ANALYSIS OF CHALLENGES AND POLICY SOLUTIONS IDENTIFIED IN MANUFACTURERS' COMMENTS IN RESPONSE TO INTERNATIONAL REFERENCE PRICE-BASED PROPOSALS
Aug 11, 2026, 17:16 PM
